Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform. Alcyone Therapeutics’ lead programs target the treatment of Rett syndrome and spinal muscular atrophy with respiratory distress type 1 (SMARD1). 

Biotechnology

Alcyone Therapeutics

Pj Anand

Natalia Podporina

Todd Washburn

Stephen Oesterle

Rich Upton

Kathrin Meyer

John L. McGuire

Greg Smith

David Johnson

Burt Raymond

Andrew East

Ravi Mehrotra

Clinical and Regulatory Affairs

Leadership Team

Research and Development

Program and Project Management

Finance and Administration

��

Teams at Alcyone Therapeutics

Clinical and Regulatory Affairs

Leadership Team

Research and Development

Program and Project Management

Finance and Administration

��������

Teams at Alcyone Therapeutics

Clinical and Regulatory Affairs

Leadership Team

Research and Development

Program and Project Management

Finance and Administration

��